Сообщение об ошибке

User warning: The following theme is missing from the file system: WORKING_COPY. For information about how to fix this, see the documentation page. в функции _drupal_trigger_error_with_delayed_logging() (строка 1156 в файле /home/insysbi8/insysbio.com/docs/includes/bootstrap.inc).

InSysBio to announce the release of its new database Cytocon DB 1.1

 

March 31, 2020

Cytocon DB 1.1 facilitates access of QSP modelers to baseline in vivo data in public domain

(Moscow - 31.03.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) platform development and provision, has released its new Cytocon DB 1.1. The name of the database derives from Cell and cYTOkine CONcentrations. The report about the significance and core principals of the Database was presented in frames of 13th InSysBio Annual Internal Scientific Meeting. In general, the database allows to investigate concentration of multiple species measured in different tissues of patients. Actually, these species embrace the cells and cytokines concentrations observed in healthy people and patients who undergo treatment and those who don’t.

The development of the web application was launched about a year ago. And now it has come into operation with the major scope of features implemented. Ekaterina Mogilevskaya, InSysBio Head of Cytocon DB team, outlines, “To maintain the system operation in a proper way, my project team is constantly updating the database adding new information to make it respond to evolving number of requests. There are constantly appearing the data that demand monitoring and incorporating. Moreover, we are adding new table fields and developing new ideas thus steadily enhancing the database”. In fact, to absorb all the scope of information the group of experts is reviewing and annotating medical articles and clinical trials results, sorting out the necessary data from these sources. The most meaningful sections comprise quantitative characteristics of patients, illnesses, and specie concentrations. Despite the fact that the data is constantly being introduced, now it already provides 3921 entries with cytokines and cell concentrations from more than 325 scientific papers.

Shedding the light on the process of Cytocon DB 1.1 development it can be highlighted that substantial attention was paid to QC implemented in the workflow. Indeed, three functional groups of the team are involved in the process: reviewers, annotators and the database manager. Particularly, the information gets through several levels of verification before being published in the database.

The web application provides the available information after the searching parameters are set in table fields, such as types of identifiers (cells, molecules, cytokines etc), illnesses, target audiences with all possible characteristics. It is important to note that various articles and clinical trials contain data on different indicators that are presented in alternative units of calculation that makes comparison difficult. InSysBio Cytocon DB team experts reconsider all the published results so that they can easily be compared in unified units. In fact, a user has an access to concentrations values expressed in both original and unified units.

Additionally, Cytocon DB 1.1 provides the opportunity to get the requested information in the most convenient form both table and graphic. It also exports search results in csv format if necessary. The web application is aimed at both external and internal use.

For more information about Cytocon DB 1.1, please visit cytocon.insysbio.com.

About InSysBio:

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

Tags: 
программы
пресс-релиз